# Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

> **NCT00601900** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 394 (actual)

## Conditions studied

- Invasive Breast Carcinoma
- Recurrent Breast Carcinoma
- Stage III Breast Cancer AJCC v6
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Letrozole
- **OTHER:** Questionnaire Administration
- **DRUG:** Tamoxifen Citrate

## Key facts

- **NCT ID:** NCT00601900
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09-24
- **Primary completion:** 2014-06-30
- **Final completion:** 2025-05-01
- **Target enrollment:** 394 (ACTUAL)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00601900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00601900, "Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00601900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*